Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clinical Rheumatol. 2010; 29 :707–716. A systematic review of results of off-label use of rituximab for autoimmune disease.Murray E. & Perry M. Off-label use of rituximab in systemic lupus erythematosus: a ...
To explore the current state of research on off-label drug use in children and identify the existing research gaps in this topic. Six literature databases
This non-approved use is called "off-label" drug use [ 2 ]. Our work area focuses on cytostatic drugs, and we know that the "off-label" use of these drugs become a common practice in some hospitals [ 3 – 5 ]. For example, Conde-García M et al. [ 3 ] found that Rituximab ...
Objective: To review the literature regarding the efficacy and safety of off-label use of apremilast in combination therapies for psoriasis and psoriatic arthritis and for other currently off-label inflammatory dermatoses. Methods: The Medline database was queried for all relevant articles published be...
Off-label use of rituximab in a tertiary Queensland hospital Butterly et al. Off-label use of rituximab Rituximab is a monoclonal antibody directed against CD20, a pan B lymphocyte marker. It is approved in Australia for treatment of CD20-positive B cell non-... Butterly, S. J.,Pillans,...
BackgroundThe therapeutic indications for rituximab are: Hodgkin9s lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis.PurposeThe aim of this study was to review the off-label use of rituximab in our hospital.Materials and methodsRetrospective study of rituximab in off-label indications from...
multiple sclerosisoff‐label prescriptionpharmacotherapyrituximab side effectsObjectives Off‐label use of rituximab to treat MSdoi:10.1111/ane.12963Berntsson S. G.Kristoffersson A.Bostr?m I.Feresiadou A.Burman J.Landtblom A. M.Acta Neurologica Scandinavica...
Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute Disclosures: Off Label Use: Off-label bendamustine and bortezomib in first-line treatment for lymphoma. Boccia: Cephalon: Research Funding.doi:10.118...
Rituximab is not only expensive, but its safety in unregistered indications is uncertain. We performed a retrospective review of the off-label use of rituximab approved by the High Cost Drug Subcommittee at the Princess Alexandra Hospital between 2005 and 2008. C...
RituximabPemphigusPemphigoidEpidermolysisDermatomyositisVasculitisPurpose of Review: Rituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This ...